287 related articles for article (PubMed ID: 25330366)
1. Effect of Eye Drops Containing Disulfiram and Low-Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models.
Nagai N; Yoshioka C; Mano Y; Ito Y; Okamoto N; Shimomura Y
Curr Eye Res; 2015; 40(10):990-1000. PubMed ID: 25330366
[TBL] [Abstract][Full Text] [Related]
2. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-β-cyclodextrin in rabbit.
Ito Y; Nagai N; Shimomura Y
Biol Pharm Bull; 2010; 33(9):1574-8. PubMed ID: 20823577
[TBL] [Abstract][Full Text] [Related]
3. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure.
Nagai N; Yoshioka C; Mano Y; Tnabe W; Ito Y; Okamoto N; Shimomura Y
Exp Eye Res; 2015 Mar; 132():115-23. PubMed ID: 25633346
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic evaluation of the anti-cataract effect of eye drops containing disulfiram and low-substituted methylcellulose using ICR/f rats as a hereditary cataract model.
Nagai N; Ito Y; Takeuchi N
Biol Pharm Bull; 2012; 35(2):239-45. PubMed ID: 22293355
[TBL] [Abstract][Full Text] [Related]
6. Reduction of enhanced rabbit intraocular pressure by instillation of pyroglutamic acid eye drops.
Ito Y; Nagai N; Okamoto N; Shimomura Y; Nakanishi K; Tanaka R
Biol Pharm Bull; 2013; 36(6):1017-23. PubMed ID: 23727922
[TBL] [Abstract][Full Text] [Related]
7. Delay in ICR/f rat lens opacification by the instillation of eye drops containing disulfiram and hydroxypropyl-beta-cyclodextrin inclusion complex.
Nagai N; Takeda M; Ito Y; Takeuchi N; Kamei A
Biol Pharm Bull; 2007 Aug; 30(8):1529-34. PubMed ID: 17666815
[TBL] [Abstract][Full Text] [Related]
8. Effects of instillation of eyedrops containing disulfiram and hydroxypropyl-β-cyclodextrin inclusion complex on endotoxin-induced uveitis in rats.
Kanai K; Ito Y; Nagai N; Itoh N; Hori Y; Chikazawa S; Hoshi F; Higuchi S
Curr Eye Res; 2012 Feb; 37(2):124-31. PubMed ID: 22029776
[TBL] [Abstract][Full Text] [Related]
9. Effect of disulfiram eye drops on lipid peroxide formation via excessive nitric oxide in lenses of hereditary cataract ICR/f rats.
Nagai N; Ito Y; Takeuchi N
Biol Pharm Bull; 2008 May; 31(5):981-5. PubMed ID: 18451530
[TBL] [Abstract][Full Text] [Related]
10. [Design of Novel Ophthalmic Formulation Containing Drug Nanoparticles and Its Usefulness as Anti-glaucoma Drugs].
Nagai N
Yakugaku Zasshi; 2016; 136(10):1385-1390. PubMed ID: 27725388
[TBL] [Abstract][Full Text] [Related]
11. An Ophthalmic Formulation of Disulfiram Nanoparticles Prolongs Drug Residence Time in Lens.
Nagai N; Mano Y; Ito Y
Biol Pharm Bull; 2016; 39(11):1881-1887. PubMed ID: 27803460
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure.
Lorenzo-Soler L; Olafsdottir OB; Garhöfer G; Jansook P; Kristinsdottir IM; Tan A; Loftsson T; Stefansson E
Acta Ophthalmol; 2021 Jun; 99(4):376-382. PubMed ID: 33191620
[TBL] [Abstract][Full Text] [Related]
13. Intraocular pressure lowering effects of novel arylpiperazine derivatives.
Chiang CH; Chang TJ; Lu DW; Lee AR
J Ocul Pharmacol Ther; 1998 Aug; 14(4):313-22. PubMed ID: 9715434
[TBL] [Abstract][Full Text] [Related]
14. Topical application of a nitric oxide synthase inhibitor reduces intraocular pressure in rabbits with experimental glaucoma.
Giuffrida S; Bucolo C; Drago F
J Ocul Pharmacol Ther; 2003 Dec; 19(6):527-34. PubMed ID: 14733710
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of HPMC-based pirfenidone solution in vivo.
Yang M; Yang YF; Lei M; Ye CT; Zhao CS; Xu JG; Wu KL; Yu MB
Drug Dev Ind Pharm; 2017 Jan; 43(1):171-176. PubMed ID: 27593737
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans.
Kristinsson JK; Fridriksdóttir H; Thórisdóttir S; Sigurdardóttir AM; Stefánsson E; Loftsson T
Invest Ophthalmol Vis Sci; 1996 May; 37(6):1199-203. PubMed ID: 8631635
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S
Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797
[TBL] [Abstract][Full Text] [Related]
18. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
19. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
